Shionogi and Tetra expand partnership ahead of Alzheimer's t...

Shionogi has expanded its partnership with its Alzheimer’s drug development partner Tetra Therapeutics, giving an option for a buyout of the US biotech ahead of a key trial milestone.

Boehringer bags CHMP backing for Ofev in rare lung disease

UK's NHS to fund Shionogi's Mulpleo after backing from NICE ...

Shionogi’s Mulpleo for severely low levels of blood platelets caused by liver disease is to be made available to NHS patients across the UK after authorities in England and Scotland said it

Roche's Tamiflu successor on target in phase 3 trial

A trial of Roche’s successor to flu medicine Tamiflu has met its goal in a phase 3 trial, with results showing that the new drug Xofluza is well tolerated in children with the flu.

ViiV's Dovato HIV pill approved in EU

ViiV’s new daily HIV treatment has been approved in the EU, as the company aims to win over patients with a more convenient treatment approach.

Sandoz to commercialise opioid induced constipation tablet i...

As it continues to look into drugs that can help opioid-dependant patients, Sandoz has signed an agreement with Shionogi to commercialise Rizmoic (naldemedine) in the key European markets